The structural heart devices market size has grown strongly in recent years. It will grow from $9.5 billion in 2023 to $10.4 billion in 2024 at a compound annual growth rate (CAGR) of 9.5%. The historical growth can be attributed to several factors, including the shift towards less invasive surgical techniques, the demand for minimally invasive structural heart devices, ongoing training and education programs for healthcare professionals, rising healthcare expenditure, and growing patient preference for non-surgical or minimally invasive treatment options.
The structural heart devices market size is expected to see strong growth in the next few years. It will grow to $15.06 billion in 2028 at a compound annual growth rate (CAGR) of 9.7%. The anticipated growth in the forecast period can be attributed to several factors, including the increasing aging population, growing awareness about heart health, the implementation of screening programs, favorable reimbursement policies for structural heart procedures, and timely regulatory approvals for new structural heart devices. Major trends expected in the forecast period encompass increasing adoption of transcatheter valve replacement, ongoing development of innovative devices with advanced materials, growing emphasis on personalized treatment approaches, increasing adoption of hybrid procedures, and integration of remote monitoring and telehealth solutions.
The increasing prevalence of cardiovascular diseases is poised to drive the expansion of the structural heart device market in the foreseeable future. Cardiovascular diseases (CVDs) encompass a range of conditions affecting the heart and blood vessels, such as coronary artery disease, heart attacks, and strokes. The incidence of cardiovascular diseases, which include heart disease and stroke, has been steadily rising worldwide due to factors such as sedentary lifestyles, poor dietary habits, increasing obesity rates, smoking, and aging populations. Structural heart devices play a crucial role in treating cardiovascular diseases by repairing or replacing damaged heart valves, correcting structural defects, and enhancing heart function and patient outcomes. For example, in January 2024, a report by the American Heart Association revealed that cardiovascular disease caused 931,578 deaths in the US, slightly up from 928,741 in 2020. Globally, there were 19.91 million CVD deaths in 2021, compared to 19.05 million in 2020. Hence, the escalating prevalence of cardiovascular diseases is fostering the growth of the structural heart device market.
Leading companies in the structural heart devices market are focusing on developing minimally invasive treatment techniques and devices to improve patient outcomes, shorten recovery periods, and broaden treatment options for structural heart conditions. A notable example is the self-expanding transcatheter aortic valve implantation (TAVI) system, designed to deploy and secure the replacement valve within the native aortic valve anatomy without the need for balloon inflation. For instance, in December 2022, Abbott Laboratories introduced Navitor, the latest-generation transcatheter aortic valve implantation (TAVI) system, in India. Navitor is specifically tailored for individuals with severe aortic stenosis at high or extreme surgical risk and incorporates advancements such as a unique design to prevent valve leakage. This innovation expands Abbott's structural heart transcatheter portfolio, offering both physicians and patients minimally invasive treatment alternatives for heart diseases. Navitor stands out as the sole self-expanding TAVI system with intra-annular leaflets and large frame cells, facilitating improved access to coronary arteries for potential future interventions in coronary artery disease (CAD). Additionally, this new design enhances hemodynamics, optimizing blood flow.
In February 2022, Genesis MedTech Group completed the acquisition of JC Medical (JCM) for an undisclosed sum. This strategic move allows Genesis to augment its product portfolio by including J-Valve, a minimally invasive transcatheter aortic valve replacement (TAVR) device designed for both aortic regurgitation and stenosis patients. JC Medical (JCM) is a US-based company specializing in the manufacture of structural heart devices.
Major companies operating in the structural heart devices market are Abbott Laboratories, Medtronic Plc, Boston Scientific Corporation, Terumo Corporation, Edwards Lifesciences Corporation, W. L. Gore & Associates Inc., Bracco Group, LivaNova PLC, Meril Life Sciences Pvt. Ltd., CryoLife Inc., Braile Biomédica, TTK Healthcare Limited, Direct Flow Medical Inc., JenaValve Technology Inc., Micro Interventional Devices Inc., CardioKinetix Inc., Xeltis AG, Ancora Heart Inc., JOMDD Inc., Valcare Medical, BioStable Science & Engineering Inc., Comed B.V., Transcatheter Technologies GmbH, Navilyst Medical Inc.
North America was the largest region in the structural heart devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the structural heart devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the structural heart devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Structural heart devices are specialized medical implants or tools tailored for treating various structural defects or abnormalities affecting the heart. They are utilized to repair or replace damaged heart structures, such as valves or septa, thereby restoring normal heart functions and enhancing patient outcomes.
The primary types of structural heart devices include heart valve devices, annuloplasty rings, occluders, and delivery systems. Heart valve devices are medical tools crafted to repair or replace damaged heart valves, ensuring proper blood flow through the heart. These procedures encompass replacement procedures, repair procedures for indications such as atrial septal defect, patent foramen ovale, ventricular septal defect, aortic valve stenosis, and others, catering to age group categories including pediatrics and adults.
The structural heart devices market research report is one of a series of new reports that provides structural heart devices market statistics, including structural heart devices industry global market size, regional shares, competitors with a structural heart devices market share, detailed structural heart devices market segments, market trends and opportunities, and any further data you may need to thrive in the structural heart devices industry. This structural heart devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The structural heart devices market consists of sales of paravalvular leak closure devices, endovascular stents, and percutaneous mitral valve replacement. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The structural heart devices market size is expected to see strong growth in the next few years. It will grow to $15.06 billion in 2028 at a compound annual growth rate (CAGR) of 9.7%. The anticipated growth in the forecast period can be attributed to several factors, including the increasing aging population, growing awareness about heart health, the implementation of screening programs, favorable reimbursement policies for structural heart procedures, and timely regulatory approvals for new structural heart devices. Major trends expected in the forecast period encompass increasing adoption of transcatheter valve replacement, ongoing development of innovative devices with advanced materials, growing emphasis on personalized treatment approaches, increasing adoption of hybrid procedures, and integration of remote monitoring and telehealth solutions.
The increasing prevalence of cardiovascular diseases is poised to drive the expansion of the structural heart device market in the foreseeable future. Cardiovascular diseases (CVDs) encompass a range of conditions affecting the heart and blood vessels, such as coronary artery disease, heart attacks, and strokes. The incidence of cardiovascular diseases, which include heart disease and stroke, has been steadily rising worldwide due to factors such as sedentary lifestyles, poor dietary habits, increasing obesity rates, smoking, and aging populations. Structural heart devices play a crucial role in treating cardiovascular diseases by repairing or replacing damaged heart valves, correcting structural defects, and enhancing heart function and patient outcomes. For example, in January 2024, a report by the American Heart Association revealed that cardiovascular disease caused 931,578 deaths in the US, slightly up from 928,741 in 2020. Globally, there were 19.91 million CVD deaths in 2021, compared to 19.05 million in 2020. Hence, the escalating prevalence of cardiovascular diseases is fostering the growth of the structural heart device market.
Leading companies in the structural heart devices market are focusing on developing minimally invasive treatment techniques and devices to improve patient outcomes, shorten recovery periods, and broaden treatment options for structural heart conditions. A notable example is the self-expanding transcatheter aortic valve implantation (TAVI) system, designed to deploy and secure the replacement valve within the native aortic valve anatomy without the need for balloon inflation. For instance, in December 2022, Abbott Laboratories introduced Navitor, the latest-generation transcatheter aortic valve implantation (TAVI) system, in India. Navitor is specifically tailored for individuals with severe aortic stenosis at high or extreme surgical risk and incorporates advancements such as a unique design to prevent valve leakage. This innovation expands Abbott's structural heart transcatheter portfolio, offering both physicians and patients minimally invasive treatment alternatives for heart diseases. Navitor stands out as the sole self-expanding TAVI system with intra-annular leaflets and large frame cells, facilitating improved access to coronary arteries for potential future interventions in coronary artery disease (CAD). Additionally, this new design enhances hemodynamics, optimizing blood flow.
In February 2022, Genesis MedTech Group completed the acquisition of JC Medical (JCM) for an undisclosed sum. This strategic move allows Genesis to augment its product portfolio by including J-Valve, a minimally invasive transcatheter aortic valve replacement (TAVR) device designed for both aortic regurgitation and stenosis patients. JC Medical (JCM) is a US-based company specializing in the manufacture of structural heart devices.
Major companies operating in the structural heart devices market are Abbott Laboratories, Medtronic Plc, Boston Scientific Corporation, Terumo Corporation, Edwards Lifesciences Corporation, W. L. Gore & Associates Inc., Bracco Group, LivaNova PLC, Meril Life Sciences Pvt. Ltd., CryoLife Inc., Braile Biomédica, TTK Healthcare Limited, Direct Flow Medical Inc., JenaValve Technology Inc., Micro Interventional Devices Inc., CardioKinetix Inc., Xeltis AG, Ancora Heart Inc., JOMDD Inc., Valcare Medical, BioStable Science & Engineering Inc., Comed B.V., Transcatheter Technologies GmbH, Navilyst Medical Inc.
North America was the largest region in the structural heart devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the structural heart devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the structural heart devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Structural heart devices are specialized medical implants or tools tailored for treating various structural defects or abnormalities affecting the heart. They are utilized to repair or replace damaged heart structures, such as valves or septa, thereby restoring normal heart functions and enhancing patient outcomes.
The primary types of structural heart devices include heart valve devices, annuloplasty rings, occluders, and delivery systems. Heart valve devices are medical tools crafted to repair or replace damaged heart valves, ensuring proper blood flow through the heart. These procedures encompass replacement procedures, repair procedures for indications such as atrial septal defect, patent foramen ovale, ventricular septal defect, aortic valve stenosis, and others, catering to age group categories including pediatrics and adults.
The structural heart devices market research report is one of a series of new reports that provides structural heart devices market statistics, including structural heart devices industry global market size, regional shares, competitors with a structural heart devices market share, detailed structural heart devices market segments, market trends and opportunities, and any further data you may need to thrive in the structural heart devices industry. This structural heart devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The structural heart devices market consists of sales of paravalvular leak closure devices, endovascular stents, and percutaneous mitral valve replacement. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Structural Heart Devices Market Characteristics3. Structural Heart Devices Market Trends and Strategies32. Global Structural Heart Devices Market Competitive Benchmarking33. Global Structural Heart Devices Market Competitive Dashboard34. Key Mergers and Acquisitions in the Structural Heart Devices Market
4. Structural Heart Devices Market - Macro Economic Scenario
5. Global Structural Heart Devices Market Size and Growth
6. Structural Heart Devices Market Segmentation
7. Structural Heart Devices Market Regional and Country Analysis
8. Asia-Pacific Structural Heart Devices Market
9. China Structural Heart Devices Market
10. India Structural Heart Devices Market
11. Japan Structural Heart Devices Market
12. Australia Structural Heart Devices Market
13. Indonesia Structural Heart Devices Market
14. South Korea Structural Heart Devices Market
15. Western Europe Structural Heart Devices Market
16. UK Structural Heart Devices Market
17. Germany Structural Heart Devices Market
18. France Structural Heart Devices Market
19. Italy Structural Heart Devices Market
20. Spain Structural Heart Devices Market
21. Eastern Europe Structural Heart Devices Market
22. Russia Structural Heart Devices Market
23. North America Structural Heart Devices Market
24. USA Structural Heart Devices Market
25. Canada Structural Heart Devices Market
26. South America Structural Heart Devices Market
27. Brazil Structural Heart Devices Market
28. Middle East Structural Heart Devices Market
29. Africa Structural Heart Devices Market
30. Structural Heart Devices Market Competitive Landscape and Company Profiles
31. Structural Heart Devices Market Other Major and Innovative Companies
35. Structural Heart Devices Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Structural Heart Devices Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on structural heart devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for structural heart devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The structural heart devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Heart Valve Devices; Annuloplasty Rings; Occluders; Delivery Systems2) By Procedure: Replacement Procedures; Repair Procedures
3) By Indication: Atrial Septal Defect; Patent Foramen Ovale; Ventricular Septal Defect; Aortic Valve Stenosis; Other Indications
4) By Age Group: Pediatric; Adults
Key Companies Mentioned: Abbott Laboratories; Medtronic Plc; Boston Scientific Corporation; Terumo Corporation; Edwards Lifesciences Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Medtronic Plc
- Boston Scientific Corporation
- Terumo Corporation
- Edwards Lifesciences Corporation
- W. L. Gore & Associates Inc.
- Bracco Group
- LivaNova PLC
- Meril Life Sciences Pvt. Ltd.
- CryoLife Inc.
- Braile Biomédica
- TTK Healthcare Limited
- Direct Flow Medical Inc.
- JenaValve Technology Inc.
- Micro Interventional Devices Inc.
- CardioKinetix Inc.
- Xeltis AG
- Ancora Heart Inc.
- JOMDD Inc.
- Valcare Medical
- BioStable Science & Engineering Inc.
- Comed B.V.
- Transcatheter Technologies GmbH
- Navilyst Medical Inc.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 175 |
Published | July 2024 |
Forecast Period | 2024 - 2028 |
Estimated Market Value ( USD | $ 10.4 Billion |
Forecasted Market Value ( USD | $ 15.06 Billion |
Compound Annual Growth Rate | 9.7% |
Regions Covered | Global |